Results 41 to 50 of about 3,462 (164)
VIEW, EarlyView.Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Site‐specific antibody modification is a useful chemical strategy to elaborate antibody therapeutic function. Conventional lysine‐ or cysteine‐based conjugation methods generate heterogeneous products, while protein engineering approaches are resource‐intensive.
Karolina Krygier +2 more
wiley +1 more source
Engineered mRNA and the Rise of Next-Generation Antibodies
Antibodies, 2021 Monoclonal antibodies are widely used as therapeutic agents in medicine. However, clinical-grade proteins require sophisticated technologies and are extremely expensive to produce, resulting in long lead times and high costs.
Laura Sanz, Luis Álvarez-Vallina
doaj +1 more source
CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems
The FEBS Journal, EarlyView.Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén +11 more
wiley +1 more source
Possible Gardens: cosmopolitical worlds
Frontiers in Environmental Science, 2023 This article presents some of the reflections produced by the Possible Gardens research, which explores the world of gardens where living beings interact directly, creating multispecific worlds.
Luciana Souza Bragança
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 614-638, September 2026.Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu +6 more
wiley +1 more source
Scientific Reports, 2023 The landscape of current cancer immunotherapy is dominated by antibodies targeting PD-1/PD-L1 and CTLA-4 that have transformed cancer therapy, yet their efficacy is limited by primary and acquired resistance. The blockade of additional immune checkpoints,
Riyao Yang +14 more
doaj +1 more source
VERITAS: Harnessing the power of nomenclature in biologic discovery
mAbs, 2023 We are entering an era in which therapeutic proteins are assembled using building block-like strategies, with no standardized schema to discuss these formats. Existing nomenclatures, like AbML, sacrifice human readability for precision.
Riti Biswas +6 more
doaj +1 more source
Biotechnology Journal, Volume 21, Issue 8, August 2026.Graphical Abstract and Lay Summary In this study, we systematically evaluated bicistronic vector designs within the piggyBac transposon system and identified that dual CMV promoters driving a Light chain‐GS‐Heavy chain configuration deliver optimal monoclonal antibody productivity.
Jason Vitko +10 more
wiley +1 more source
Current landscape and future directions of bispecific antibodies in cancer immunotherapy
Frontiers in Immunology, 2022 Recent advances in cancer immunotherapy using monoclonal antibodies have dramatically revolutionized the therapeutic strategy against advanced malignancies, inspiring the exploration of various types of therapeutic antibodies.
Jing Wei +3 more
doaj +1 more source